Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Ionis Pharmaceuticals: Clinical Trials & FDA Approval Profile

Ionis Pharmaceuticals (Global / Institutional) sponsors 43 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 17 active protocols (7 recruiting now), 23 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)7.0%
Median Closed Enrollment vs National (145 pts)71 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Ionis Pharmaceuticals
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)43
Active Pipeline (Recruiting Now)17 (7)
Completed vs Stopped Early23 / 3 (7.0%)
Median Closed Actual Enrollment71 participants
Physical Hospital Site Disclosure86.6% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Ionis Pharmaceuticals
Hospital Research SiteLocationShared Protocols
Massachusetts General HospitalBoston, MA8
Columbia University Irving Medical CenterNew York, NY7
Oregon Health and Science University Knight Cancer InstitutePortland, OR7

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Ionis Pharmaceuticals
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04768972FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis ParticipaPhase IIIACTIVE NOT RECRUITING
NCT05071300A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in PatienPhase IIIACTIVE NOT RECRUITING
NCT05185843A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously TrPhase IIIACTIVE NOT RECRUITING
NCT04849741A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)Phase IIIACTIVE NOT RECRUITING
NCT05130450A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)Phase IIIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Ionis Pharmaceuticals Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI